Literature DB >> 17318614

The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice.

Julia Metzner1, Laura Popp, Claudiu Marian, Ronald Schmidt, Christine Manderscheid, Christoph Renne, Beate Fisslthaler, Ingrid Fleming, Rudi Busse, Gerd Geisslinger, Ellen Niederberger.   

Abstract

In this study, we investigated the effects of prolonged administration of the selective COX-2 inhibitors celecoxib and rofecoxib and the non-selective NSAID naproxen on the initiation and progression of atherosclerosis. ApoE(-/-) mice, as well as corresponding wild-type mice, were fed either a normal chow or a high fat Western diet with or without addition of the respective drugs over a period of 16 weeks. Thereafter, aortic lesion size, plasma lipid levels, and COX-2 expression in the plaques were determined. The results showed that neither the COX-2 selective inhibitors nor naproxen had a significant impact on the initiation and progression of atherosclerosis in diet-fed ApoE(-/-) mice, although both celecoxib and rofecoxib showed a tendency to reduce plaque size. This slight effect may be due to selective inhibition of COX-2 activity because the COX-2 expression was not altered in the plaque. Plasma lipid levels were also not significantly influenced by these drugs. Interestingly, in ApoE(-/-) mice that have been fed with normal chow, we found an increased incidence of plaque formation after treatment with celecoxib and rofecoxib, indicating that coxibs may promote the initiation of atherosclerosis. This effect was probably masked in diet-fed mice by the more pronounced effects of the high cholesterol diet. In conclusion, the reduction in diet-induced plaque size in animals fed a high fat diet and the promotion of atherosclerosis in mice on a normal diet indicate a dual role of the coxibs. In advanced stages of atherosclerosis, they may exert antithrombotic properties due to their COX-2 inhibiting activity, whereas in very early stages they may favor the initiation of atherogenesis. However, because these results were only observed in ApoE(-/-) and not in wild-type animals, coxibs may increase the risk of thrombosis in patients with a predisposition for thrombotic complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318614     DOI: 10.1007/s00109-007-0162-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   5.606


  39 in total

1.  Determination of celecoxib in human plasma by normal-phase high-performance liquid chromatography with column switching and ultraviolet absorbance detection.

Authors:  M J Rose; E J Woolf; B K Matuszewski
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-02-11

Review 2.  Topological proteomics, toponomics, MELK-technology.

Authors:  Walter Schubert
Journal:  Adv Biochem Eng Biotechnol       Date:  2003       Impact factor: 2.635

3.  The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice.

Authors:  A Paul; L Calleja; J Camps; J Osada; E Vilella; N Ferré; E Mayayo; J Joven
Journal:  Life Sci       Date:  2000-12-15       Impact factor: 5.037

Review 4.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

5.  Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries.

Authors:  V Stemme; J Swedenborg; H Claesson; G K Hansson
Journal:  Eur J Vasc Endovasc Surg       Date:  2000-08       Impact factor: 7.069

6.  In vivo endothelial interaction between ACE and COX inhibitors.

Authors:  R J Gryglewski; S Chlopicki; J Swies
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2005-02       Impact factor: 4.006

7.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

8.  The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia.

Authors:  Susanne Kunz; Ellen Niederberger; Corina Ehnert; Ovidiu Coste; Anja Pfenninger; Jochen Kruip; Thomas M Wendrich; Achim Schmidtko; Irmgard Tegeder; Gerd Geisslinger
Journal:  Pain       Date:  2004-07       Impact factor: 6.961

9.  Selective COX-2 inhibition improves endothelial function in coronary artery disease.

Authors:  Rémy Chenevard; David Hürlimann; Markus Béchir; Frank Enseleit; Lukas Spieker; Matthias Hermann; Walter Riesen; Steffen Gay; Renate E Gay; Michel Neidhart; Beat Michel; Thomas F Lüscher; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 10.  Cyclooxygenase-2 and inflammation in atherosclerosis.

Authors:  MacRae F Linton; Sergio Fazio
Journal:  Curr Opin Pharmacol       Date:  2004-04       Impact factor: 5.547

View more
  6 in total

1.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

2.  Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits.

Authors:  F I Romero; M J Martínez-Calatrava; O Sánchez-Pernaute; O Gualillo; R Largo; G Herrero-Beaumont
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors.

Authors:  Ajay Narasimha; Junji Watanabe; James A Lin; Susan Hama; Robert Langenbach; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-03-14       Impact factor: 3.072

4.  Atherosclerosis and rheumatoid arthritis: more than a simple association.

Authors:  Lorenzo Cavagna; Nicola Boffini; Giovanni Cagnotto; Flora Inverardi; Vittorio Grosso; Roberto Caporali
Journal:  Mediators Inflamm       Date:  2012-09-13       Impact factor: 4.711

Review 5.  New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases.

Authors:  Wujun Chen; Yingjie Zhong; Nuan Feng; Zhu Guo; Shuai Wang; Dongming Xing
Journal:  Mol Med       Date:  2021-09-30       Impact factor: 6.354

6.  Studies Based on Preparation, Physical Characteristics, and Cellular Pharmacological Activities of Thin PLGA Film Loaded with Geniposide.

Authors:  Haiyan Zhang; Hao Liu; Nan Huang; Ya He; Tingting Lei; Xin Wang; Ming Yang; Guangming Luo
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-12       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.